AAPS J 2022 03 21;24(3):45. Epub 2022 Mar 21.
Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc., RY800-D211, 126 East Lincoln Avenue, Rahway, New Jersey, 07065, USA.
Inhibitory effects of asunaprevir, daclatasvir, grazoprevir, paritaprevir, simeprevir, and voxilaprevir, direct-acting antiviral (DAA) drugs for the treatment of chronic hepatitis C virus (HCV) infection, were evaluated in vitro against a range of clinically important drug transporters. In vitro inhibition studies were conducted using transporter transfected cells and membrane vesicles. The risk of clinical drug-drug interactions (DDIs) was assessed using simplified static models recommended by regulatory agencies. Read More